KR20250143331A - 종양 조직 내에 있어서 m2 매크로파지로 분화될 수 있고, m2 매크로파지로 분화되면 염증성 사이토카인을 발현하는 세포, 및 당해 세포를 포함하는 조성물 - Google Patents
종양 조직 내에 있어서 m2 매크로파지로 분화될 수 있고, m2 매크로파지로 분화되면 염증성 사이토카인을 발현하는 세포, 및 당해 세포를 포함하는 조성물Info
- Publication number
- KR20250143331A KR20250143331A KR1020257029106A KR20257029106A KR20250143331A KR 20250143331 A KR20250143331 A KR 20250143331A KR 1020257029106 A KR1020257029106 A KR 1020257029106A KR 20257029106 A KR20257029106 A KR 20257029106A KR 20250143331 A KR20250143331 A KR 20250143331A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- macrophages
- cell
- cancer
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2023-017913 | 2023-02-08 | ||
| JP2023017913 | 2023-02-08 | ||
| PCT/JP2024/004080 WO2024166936A1 (ja) | 2023-02-08 | 2024-02-07 | 腫瘍組織内においてm2マクロファージに分化することができ、m2マクロファージに分化すると炎症性サイトカインを発現する細胞、および当該細胞を含む組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250143331A true KR20250143331A (ko) | 2025-10-01 |
Family
ID=92262742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257029106A Pending KR20250143331A (ko) | 2023-02-08 | 2024-02-07 | 종양 조직 내에 있어서 m2 매크로파지로 분화될 수 있고, m2 매크로파지로 분화되면 염증성 사이토카인을 발현하는 세포, 및 당해 세포를 포함하는 조성물 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260226412A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4663750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024166936A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250143331A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120603934A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024166936A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10362002B4 (de) | 2003-06-23 | 2006-10-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Adulte pluripotente Stammzellen |
| DK3612624T3 (da) * | 2017-04-21 | 2024-12-09 | Ospedale San Raffaele Srl | Genterapi |
| CN111868234A (zh) * | 2018-02-27 | 2020-10-30 | 斯坦福大学托管董事会 | 工程化免疫细胞作为疾病的诊断探针 |
| KR20220122636A (ko) * | 2019-12-30 | 2022-09-02 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 제1형 당뇨병을 치료하기 위한 대식세포의 췌장 내 m2 분극화 |
| JP7736286B2 (ja) * | 2020-02-10 | 2025-09-09 | 国立大学法人山口大学 | ヒトインターロイキン4受容体の変異ポリペプチド、及びm2マクロファージへの分化又は分極誘導剤 |
-
2024
- 2024-02-07 JP JP2024576877A patent/JPWO2024166936A1/ja active Pending
- 2024-02-07 EP EP24753379.7A patent/EP4663750A1/en active Pending
- 2024-02-07 US US19/154,945 patent/US20260226412A1/en active Pending
- 2024-02-07 KR KR1020257029106A patent/KR20250143331A/ko active Pending
- 2024-02-07 WO PCT/JP2024/004080 patent/WO2024166936A1/ja not_active Ceased
- 2024-02-07 CN CN202480011560.9A patent/CN120603934A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024166936A1 (ja) | 2024-08-15 |
| CN120603934A (zh) | 2025-09-05 |
| US20260226412A1 (en) | 2026-08-06 |
| JPWO2024166936A1 (cg-RX-API-DMAC7.html) | 2024-08-15 |
| EP4663750A1 (en) | 2025-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hadiloo et al. | The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors | |
| Zhu et al. | Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors | |
| Moon et al. | Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor | |
| KR20210044736A (ko) | 키메라 항원 수용체(car) t세포 요법과 키나제 억제제의 조합요법 | |
| CN117305250A (zh) | 工程化天然杀伤细胞及其用途 | |
| AU2025279705A1 (en) | Combination therapy using a chimeric antigen receptor | |
| US20240109947A1 (en) | Immunostimulatory cytokine combination and therapeutic use thereof | |
| BR112020012848A2 (pt) | célula imunocompetente, composição farmacêutica, vetor de expressão, e, método para produzir uma célula imunocompetente. | |
| KR20220152220A (ko) | Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도 | |
| CN111655843A (zh) | Nk或t细胞及其用途 | |
| CN118557714A (zh) | 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品 | |
| JP2022513412A (ja) | 癌を治療するための物質及び方法 | |
| WO2018052142A1 (ja) | 遺伝子改変細胞及びその作製方法 | |
| US20240408202A1 (en) | FOLATE RECEPTOR ALPHA -TARGETING BI-SPECIFIC T CELL ENGAGERS (BiTEs) AND USES THEREOF | |
| IL294724A (en) | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy | |
| US20220202900A1 (en) | Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia | |
| CN110392595A (zh) | 改进的基于nk细胞的疗法 | |
| TW202321287A (zh) | 特異性靶向間皮素之經工程改造之免疫細胞及其用途 | |
| JP7837864B2 (ja) | T細胞療法と(s)-3-[4-(4-モルホリン-4-イルメチル-ベンジルオキシ)-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル]-ピペリジン-2,6-ジオンとの併用 | |
| JP2021195364A (ja) | Rnaを含有する抗腫瘍剤、免疫細胞の活性化方法、腫瘍細胞の転移の抑制方法、免疫賦活剤、抗腫瘍剤の抗腫瘍効果の増強剤、及び医薬組成物 | |
| EP4663750A1 (en) | Cell capable of being differentiated into m2 macrophage in tumor tissue and having property such that m2 macrophage differentiated from said cell express inflammatory cytokine, and composition containing said cell | |
| WO2025002479A1 (zh) | 一种基于胞内区截短体的嵌合抗原受体 | |
| US20240131073A1 (en) | Mir200c-epcam axis reprogramed immune cells for enhanced anti-tumor function | |
| CN115925985A (zh) | Car-t细胞及其在非小细胞肺癌治疗中的应用 | |
| Huang et al. | Efficacy-enhanced and cytokine release syndrome-attenuated anti-CD7 universal chimeric antigen receptor-T cell therapy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |